A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn's disease.
Fiche publication
Date publication
janvier 2016
Journal
Expert opinion on drug safety
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Papamichael K, Mantzaris GJ, Peyrin-Biroulet L
Lien Pubmed
Résumé
Anti-tumor necrosis factor-alpha (TNF-α) therapy has revolutionized the medical treatment of Crohn's disease (CD). Nevertheless, anti-TNF-α therapy has been associated with serious adverse events (SAE) raising safety concerns. This review focuses on the safety profile of anti-TNF-α agents in CD.
Mots clés
Anti-TNF-α therapy, Crohn’s disease, adalimumab, certolizumab pegol, infection, inflammatory bowel disease, infliximab, malignancy, mortality, safety
Référence
Expert Opin Drug Saf. 2016 ;15(4):493-501